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Edited by Barry HalliwellAbstract Valproic acid (VPA), an anticonvulsant and mood-
stabilizing drug, has been reported to exert neuroprotection
against a variety of insults. We now show that VPA attenuates
rotenone (a potent complex I inhibitor)-induced apoptosis
through the induction of heat shock protein 70, which may inter-
act with apoptotic-protease-activating factor 1. Activation of
p-Akt, p-Bcl-2, as well as p-Erk1/2 by VPA may be co-contri-
butors to the protection.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Parkinsons disease (PD) is one of the most common neuro-
degenerative disorders, characterized by degeneration of nigral
dopaminergic (DAergic) neurons and the formation of Lewy
bodies [1]. The cause of DAergic neuron death in PD remains
unknown, but may involve oxidative stress and mitochondrial
complex I deﬁciency, which may account for the accumulation
of modiﬁed proteins and degeneration of DAergic neurons in
the brain [1]. Complex I inhibitors, such as rotenone, have
been found to cause degeneration of DAergic neurons and par-
kinsonian motor dysfunction [2,3]. Moreover, there is evidence
to suggest that nigral DAergic neuron degeneration in PD is
mediated via apoptotic pathways [4]. To identify potential tar-
gets for therapeutic intervention in PD, it is important to
determine signaling pathways linking complex I impairment
and the induction of apoptotic cell death in DAergic neurons.
Studies have shown that heat shock proteins (Hsps), a
tightly regulated group of proteins acting as molecular chaper-Abbreviations: DA, dopamine; PD, Parkinsons disease; Hsp, heat
shock protein; VPA, valproic acid; KNK437, N-formyl-3,4-methylen-
edioxy-benzylidene-gamma-butyrolactam; Apaf-1, apoptotic-protease-
activating factor 1; cyt c, cytochrome c; IP, immunoprecipitation;
GSK3, glycogen synthase kinase 3; PI3-K, phosphatidlinositol 3-
kinase; Bcl-2, B cell lymphoma protein-2; p-Erk1/2, phospho-p44/42
mitogen-activated protein kinases
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to denatured and malfolded proteins and participate in the
removal of the wasted proteins [5]. Induction or expression
of Hsps has been shown to be protective in several models of
neurodegenerative diseases including cell culture models of
Huntingtons disease and spinocerebellar ataxias, and in
drosophila model of PD [6–9]. Among several multi-member
families of Hsps, Hsp70 is one of the best characterized endog-
enous factors involved in protecting cells from injury under
various pathological conditions [10]. Several pharmacological
agents, such as valproic acid (VPA), a clinical used drug for
the treatment of seizures and bipolar mood disorder [11–13],
have been demonstrated to increase resistance to injury caused
by a variety of insults through the induction of Hsp70 [14].
In the present study, we have tested the ability of VPA in
neuroprotection against rotenone-induced apoptosis in SH-
SY5Y, a human DAergic cell line often used for study of neu-
rodegeneration mechanisms relevant to PD [15–17]. By using
this rotenone-induced apoptosis cell model, we have evaluated
the role of Hsp70 and several critical signaling pathways in-
volved in VPA-mediated neuroprotection.2. Materials and methods
2.1. Cell culture and treatments
SH-SY5Y cells were routinely grown in Dulbeccos modiﬁed Eagles
medium supplemented with 10% heat-inactivated fetal bovine serum
(GIBCO, Gaithersburg, MD) and cultured at 37 C under humidiﬁed
5% CO2 atmosphere. Rotenone (Sigma, St. Louis, MO) stocks were
made freshly in dimethyl sulfoxide prior to each experiment and cells
were exposed to various concentrations of rotenone for 24 hours (h).
To study the putative neuroprotective eﬀects of VPA, cells were pre-
treated with VPA (Sigma, St. Louis, MO) followed by the addition
of rotenone. This method is based on our preliminary study that
showed that pre-treatment, rather than post-treatment, with VPA
had preventive eﬀect against rotenone-induced apoptosis.
2.2. Apoptosis assay
For microscopic nuclear DNA analysis, cells were stained with Hoe-
chst 33342 (Molecular Probe, Eugene, Oregon, USA). The cells with
condensed nuclei as determined by ﬂuorescent microscope were con-
sidered to be apoptotic. The number of apoptotic cells was expressed
as percentage of total.
2.3. Immunoblot analysis
After speciﬁc treatment, cells were harvested by lysis buﬀer. Equal
amounts of lysate protein were separated by SDS–polyacrylamide gel
electrophoresis, followed by immunoblot analysis with various pri-
mary antibodies against Hsp70 (1:2000); apoptotic-protease-activating
factor 1 (Apaf-1) (1:500) (Santa Cruz Biotechnology, INC, Santa Cruz,blished by Elsevier B.V. All rights reserved.
Fig. 1. Rotenone-induced apoptosis and VPA-mediated anti-apoptotic
eﬀect. The levels of cleaved PARP were determined by immunoblotting
in the SH-SY5Y cells treated with rotenone at 2.5–20 lM for 24 h (A),
or rotenone at 10 lM for 0–48 h (B), or pretreated with VPA 3 h before
rotenone addition (C).
T. Pan et al. / FEBS Letters 579 (2005) 6716–6720 6717CA), poly(ADP-ribose) polymerase (PARP) and cleavage (1:500), cas-
pase-9 and cleaved caspase-9 (1:1000), caspase-3 and cleaved caspase-3
(1:1000), p-Akt(473) (1:500), phospho-B cell lymphoma protein-2 (p-
Bcl2) (1:1000), phospho-p44/42 mitogen-activated protein kinases
(MAPK) (p-Erk1/2) (1:1000), and phospho-glycogen synthase kinase
3 a/b (p-GSK3a/b) (1:1000), (Cell Signaling Technology, Beverly,
MA) separately. Cytosolic fraction was isolated from the cell pellets
according to the previous report [18] and ﬁfteen micrograms protein
of cytosol was subjected to immunoblotting assay with cytochrome c
(cyt c, 1:250; BD Biosciences Pharmingen, San Diego, CA). Mem-
branes were washed and exposed to the second antibody. Speciﬁc sig-
nals were visualized using the enhanced chemiluminescence detectionFig. 2. VPA-mediated neuroprotection. The apoptosis was determined by Ho
b), rotenone (A-c), or pretreated with VPA for 3 h before rotenone additio
VPA + rotenone (A-f). Quantiﬁcation of apoptosis was expressed by mean
variance (ANOVA) (B). \: P < 0.01; \\: P < 0.05 as compared with vehicle
V = VPA; Ro = rotenone; K = KNK437.kit (Amersham, Arlington Heights, IL). Immunoblotting of b-actin
(1:2000; Chemicon, Temecula, CA) was performed to demonstrate
equal protein loading.
2.4. Immunoprecipitation (IP) of Apaf-1
After various treatments, 200 lg of total protein obtained from
whole cell lysate were incubated with 2 lg of anti-Apaf-1 antibody at
4 C for 3 h. The immunocomplexes were precipitated by incubation
with 20 ll of protein G–Sepharose (Santa Cruz Biotechnology, INC,
Santa Cruz, CA) at 4 C overnight. Immunoprecipitates were washed,
separated by SDS–polyacrylamide gel electrophoresis and then sub-
jected to immunoblotting with antibody against either Apaf-1 or
Hsp70.3. Results
3.1. Suppression of rotenone-induced apoptosis by VPA
Treatment with rotenone increased PARP cleavage at a
dose- and time-dependent manner. After the SH-SY5Y cells
were treated with rotenone at 2.5–20 lM for 24 h, the cleaved
PARP, a hallmark of apoptosis, could be clearly seen with
rotenone at 5 lM and continued to increase at the higher con-
centrations of rotenone (Fig. 1A). At 10 lM of rotenone,
cleaved PARP was obvious in 12 h and increased up to 48 h
(Fig. 1B). However, pretreatment of cells with VPA at 5 mM
for 3 h before rotenone addition signiﬁcantly reduced the
PARP fragmentations (Fig. 1C). After analyzing the micro-
scopic nuclear DNA, we found a 30% increase of apoptotic
bodies in rotenone-treated cells vs. vehicle-treated control
(P < 0.01, Fig. 2A and B); while VPA treatment signiﬁcantly
decreased rotenone-induced apoptosis by at least 50%
(P < 0.05, Fig. 2A and B).
A dose-dependent increase of cyt c levels was shown in the
cytosolic fraction obtained from rotenone-treated cells
(Fig. 3A), and the increased cyt c in cytosol was partially inhib-
ited by the pretreatment with VPA (Fig. 3B). Cleaved caspase-9
and caspase-3 proteins were increased in a dose-dependent
manner after the cells were exposed to rotenone (Fig. 3C), which
roughly coincided with the appearance of cyt c (Fig. 3A) and
of cleaved PARP (Fig. 1A). The rotenone-induced cleavage ofechst 33342 in the SH-SY5Y cells treated with vehicle (A-a), VPA (A-
n (A-d), or treated with KNK437 alone (A-e) or KNK437 1 h before
± SD and statistical diﬀerence was analyzed by one-way analysis of
treated control (a), Ro group (c), or V/Ro group (d). Con = control;
Fig. 3. Proposed anti-apoptosis pathways by VPA. Protein levels of cyt c were detected by immunoblotting in cytoplasmic fraction from SH-SY5Y
cells treated with rotenone at 2.5–20 lM for 24 h (A), or pretreated with VPA at 5 mM for 3 h followed by 10 lM of rotenone addition (B). The
cleaved caspase-9 and caspase -3 proteins were determined by immunoblotting in whole cell lysate from SH-SY5Y cells treated with rotenone at 2.5–
20 lM for 24 h (C), or pretreated with VPA at 5 mM for 3 h followed by 10 lM of rotenone addition (D).
Fig. 4. Induction of Hsp70 by VPA. The SH-SY5Y cells were treated with VPA at 0.2–10 mM for 24 h (A), or at 5 mM of VPA for 2–24 h (B). Some
of the SH-SY5Y cells were pretreated with KNK437 at 25–100 lM for 1 h before 5 mM VPA treatment (C), or pretreated with VPA at 5 mM for 3 h
before rotenone addition (D). The protein levels of Hsp70 were determined by immunoblotting. Hsp70-Apaf-1 complex formation was determined by
IP assay after VPA pretreatment at 5 mM for 3 h before 10 lM rotenone addition (E).
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ment with VPA (Fig. 3D).3.2. Induction of Hsp70 by VPA
A signiﬁcant increase of Hsp70 in SH-SY5Y cells was de-
tected after VPA treatment at 0.2–10 mM (Fig. 4A). The in-
crease was seen within 4 h at 5 mM of VPA, and reached to
a maximal level within 8–24 h (Fig. 4B). The enhanced
Hsp70 expression was blocked by a novel Hsp inhibitor, N-for-
myl-3,4-methylenedioxy-benzylidene-gamma-butyrolactam
(KNK437, EMD Biosciences, Inc. San Diego, CA) [19], in a
dose-dependent manner (Fig. 4C). Accordingly, the protective
eﬀect of VPA on rotenone-induced apoptosis was partially
abolished by KNK437 as determined by condensed nuclei
and apoptotic bodies (Fig. 2A-f). KNK437 itself, at a concen-
tration of 100 lM, did not show any toxic eﬀect on SH-SY5Y
cells (Fig. 2A-e). Rotenone exposure did not cause the change
in Hsp70 levels nor altered the VPA-mediated Hsp70 increase
(Fig. 4D). Interaction of Hsp70 with Apaf-1 as determined by
IP assay showed a signiﬁcant increase of Hsp70-Apaf-1 com-
plex formation after VPA treatment (Fig. 4E).3.3. Activation of p-Akt, p-Bcl-2 and MAP kinase pathway
Treatment with VPA upregulated p-Akt(473), p-Bcl-2, and
p-Erk1/2 in a dose- and time-dependent manner (Fig. 5A and
B), and the induction of these proteins was detected within 4–
8 h at 5 mM of VPA (Fig. 5B). The inhibition of Hsp70 by
KNK437 resulted in the decrease of p-Bcl-2 and p-Erk1/2, but
not p-Akt(473) (Fig. 5C). However, the increased p-Akt(473)
was attenuated by phosphatidlinositol 3-kinase (PI3-K)-speciﬁc
inhibitor, LY294002 (Sigma, St. Louis, MO), and accordingly,
the protein levels of p-GSK3a/b were decreased (Fig. 5D).Fig. 5. Induction of p-Akt(473), p-Bcl-2, and p-Erk1/2 by VPA. The SH-SY
5 mM for 2–24 h (B). Some of the cells were pretreated with 100 lM KNK43
VPA at 5 mM for 24 h followed by addition of 20 lM LY294002 for 10 m
p-Erk1/2 and Hsp70 were determined by immunoblotting.4. Discussion
Our study provided evidence that VPA is able to protect
DAergic neurons against rotenone-induced apoptosis through
the inhibition of cyt c release and the decrease of both cas-
pase-9 and caspase-3 production. Further, our study sug-
gested that VPA mediated increase of Hsp70 protein and
the binding of Hsp70 to Apaf-1 may be the main protective
mechanisms. Our ﬁndings are in accord to the previous re-
ports that Hsp70 indirectly inhibited cyt c/ATP-dependent
activation of caspase-3 through its eﬀect on Apaf-1-mediated
activation of caspase-9 [20–22]. However, VPA-mediated
neuroprotection was only partially blocked by Hsp70 synthe-
sis inhibitor KNK437, indicating that in addition to Hsp70
other mechanisms might have contributed to VPAs neuro-
protection.
Akt, also referred to as protein kinase B (PKB), plays a
critical role in controlling the balance between survival and
apoptosis. The fact that protein levels of p-Akt were en-
hanced by VPA and such increase was not associated with
the induction of Hsp70 implies that p-Akt may be an inde-
pendent pathway involved in the neuroprotection of VPA.
Furthermore, abolishment of the increase in Akt phosphory-
lation by PI3-K speciﬁc inhibitor LY294002 suggests that
VPA-induced activation of Akt is likely mediated through
the PI3-K dependent pathway. One of the essential functions
of Akt is to regulate glycogen synthesis through phosphoryla-
tion and inactivation of GSK3. The upregulation of both iso-
forms of GSK3 (GSK3a and b) by VPA was associated with
the increase of p-Akt, and such increase can be inhibited by
LY294002. This result is consistent with the previous reports
that Akt can phosphorylate and inactivate GSK3 through
PI3-K pathway [23,24]. Therefore, activation of PI3-K or5Y cells were treated with VPA at 0.2–10 mM for 24 h (A), or VPA at
7 for 1 h before VPA addition (C). Some of the cells were treated with
in before harvest (D). The protein levels of p-Akt(473), p-Bcl-2, and
6720 T. Pan et al. / FEBS Letters 579 (2005) 6716–6720inhibition of GSK3a/b activity may provide protection
against the rotenone-induced apoptosis [23–26].
The MAPK (Erk1/2) signaling pathway plays a critical role
in the regulation of cell growth [27]. The high levels of Bcl-2
protein, located in the outer mitochondrial wall, enhance the
survival of cells when exposed to adverse stimuli by controlling
mitochondrial permeability and cyt c release [28]. The activa-
tion of p-Erk1/2 and increase of p-Bcl-2 has been reported in
previous reports [28–30]. We consider that both of them may
contribute to the neuroprotection of VPA against rotenone-in-
duced apoptosis in SH-SY5Y cells.
Lithium, another primary drug used to treat bipolar mood
disorder, has been reported to have similar neuroprotective ef-
fects as VPA [31]. Both drugs can activate PI3-K/Akt signaling
pathway, induce neuroprotective proteins, including Hsp70, p-
Bcl-2 and p-Erk1/2, and inactivate GSK-3 [29,31]. These ﬁnd-
ings are consistent with our results, suggesting that VPA and
lithium are potential drugs for the treatment of neurodegener-
ative diseases, such as PD.
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